Roche Sees Its First Cancer Immunotherapy Winning U.S. Nod Soon
- Atezolizumab to get U.S. approval for bladder, lung cancer
- FDA likely to clear both this year, head of pharma says
This article is for subscribers only.
Roche Holding AG said its most advanced experimental drug to harness the immune system in the fight against cancer may win U.S. regulatory approval this year, becoming the first such treatment to help the roughly 430,000 people diagnosed annually with bladder cancer.
The medicine, called atezolizumab, may generate around $3 billion in sales by 2020, according to Bloomberg Intelligence. It will face competition from Bristol-Myers Squibb Co. and Merck & Co. products.